Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 10/20 | 1.00 |
| ▸ | MMP2 | P08253 | 10/20 | 1.00 |
| ▸ | MMP9 | P14780 | 10/20 | 1.00 |
| ▸ | EGFR | P00533 | 10/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KDM1A | O60341 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-(2-Fluorophenyl)Cinnamamide SCHEMBL1967607 | 1.00 | MMP1 (1.00) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL705904 | 0.89 | MMP1 (0.80) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL705905 | 0.89 | MMP1 (0.80) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL10492426 | 0.88 | MMP1 (0.80) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL10492424 | 0.88 | MMP1 (0.80) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL30159590 | 0.86 | MMP1 (0.76) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL3180639 | 0.86 | MMP1 (0.76) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL2821162 | 0.86 | MMP1 (0.76) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL2819695 | 0.86 | MMP1 (0.76) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL2821167 | 0.86 | MMP1 (0.76) | MMP1MMP2MMP9EGFRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| CN-108250128-A | Compound as potassium channel modulating agents | 江苏先声药业有限公司 | 2018-07-06 | — | — | CN | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2834231-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2137186-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-01-27 | — | — | EP | disclosed |
| US-8987251-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2015-02-12 | — | — | US | disclosed |
| EP-2834231-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| CN-102186851-A | Triazolopyridine compounds as pim kinase inhibitors | ARRAY BIOPHARMA INC | 2011-09-14 | — | — | CN | disclosed |
| EP-2334677-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110144085-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010022076-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-2137186-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-0524846-A1 | 2-(Piperidin-1-yl)ethanol derivatives, their preparation and their use in therapeutics | SYNTHELABO (FR) | 1993-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | MMP1 2900/4885MMP2 3412/4885MMP9 1782/4885 |
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | MMP1 2900/4885MMP2 3412/4885MMP9 1782/4885 |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | MMP1 2900/4885MMP2 3412/4885MMP9 1782/4885 |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | MMP1 2900/4885MMP2 3412/4885MMP9 1782/4885 |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | MMP1 2900/4885MMP2 3412/4885MMP9 1782/4885 |
| US-20110144085-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | MMP1 3567/4885MMP2 4606/4885MMP9 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.